Where does Donmienne Leung work?

Donmienne Leung is Director II, Head of AbbVie Ventures Europe at AbbVie and Board director at EndLyz Therapeutics and CEO at ThirtyFiveBio Limited.

Where did Donmienne Leung go to school?

Donmienne Leung studied at The University of Queensland (Doctor, Philosophy); University of Melbourne (Bachelor of Science (Honours), Chemistry / Biochemistry); University of Melbourne (Bachelor of Science & Bachelor of Engineering, Biochemistry).

Donmienne Leung

Investor

Director II, Head of AbbVie Ventures Europe at AbbVie · Board director at EndLyz Therapeutics · CEO at ThirtyFiveBio Limited

Oxford, England, United Kingdom

Find your path to Donmienne

254 people in our graph share verified history with Donmienne — schools, employers, funds. One of them is your warm intro.

Joanna WolakunlockedDonmienne: together at EndLyz Therapeutics (2023–2026)

×11Donmienne: together at Eli Lilly

About

Donmienne Leung leads a dedicated European venture mandate and, after 20+ years as a drug hunter and PhD medicinal chemist with active publications, provides hands-on scientific guidance to biotech boards.

Invests in

AI & Machine LearningBiotechData & InfrastructureHealthtech

Board director at EndLyz Therapeutics

Intro paths

→

In turn, Donmienne can intro founders to EndLyz Therapeutics's investors below.

EndLyz Therapeutics's investors · 2

Dementia Discovery FundLondon Oxford Science EnterprisesOxford · $63.5K – $31.8M checks

CEO at ThirtyFiveBio Limited

Intro paths

→

In turn, Donmienne can intro founders to ThirtyFiveBio Limited's investors below.

ThirtyFiveBio Limited's investors · 1

Canaan PartnersStamford · $500K – $20M checks · since 2025

Experience

AbbVieDirector II, Head of Ventures Europecurrent2025 — presentOxford
AbbVieDirector, AbbVie Ventures UK/Europe2023 — 2025Oxford, England, United Kingdom
ThirtyFiveBioBoard Membercurrent2025 — present
CephagenixBoard Membercurrent2025 — presentParis and Copenhagen
EvolveImmune TherapeuticsBoard Membercurrent2024 — presentBranford, Connecticut, United States
Endlyz TherapeuticsBoard Membercurrent2023 — presentOxford, England, United Kingdom
Enthera PharmaceuticalsBoard Observer2023 — 2025Milan, Lombardy, Italy
DISCO Pharmaceuticals GmbHBoard Observer2023 — 2025Cologne, North Rhine-Westphalia, Germany
Absolute BiotechHead of Protein Engineering2021 — 2023Redcar
Eli Lilly and CompanySenior Research Advisor2020 — 2021
Eli Lilly and CompanyResearch Advisor2017 — 2020Greater San Diego Area
Eli Lilly and CompanyPrinicipal Research Scientist2012 — 2017
Eli Lilly and CompanySenior Research Scientist2008 — 2012
Eli Lilly and CompanyResearch Scientist2005 — 2008
The Scripps Research InstitutePostdoctoral Scientist2001 — 2005San Diego, California, United States
University of QueenslandPHD Student1997 — 2001Brisbane, Australia
University of MelbourneHonors Student1996 — 1997Melbourne, Victoria, Australia
Walter and Eliza Hall Institute of Medical ResearchResearch Assistant1994 — 1996Melbourne, Victoria, Australia

Skills & more

ResearchBiopharmaceuticalsDrug Discovery26Protein Engineering10Chemistry5Antibodies9Protein Chemistry14Chemical Biology2Biochemistry13Protein Purification3Assay Development2Molecular Biology6

+12 more

HPLCDrug DevelopmentMedicinal ChemistryCell BiologyCell CultureBiotechnologyImmunologyELISAChromatographyWestern BlottingVolunteeringDrug Design

Languages Chinese · English

VC University — VC University

From Donmienne's professional profile.

Colleagues at AbbVie

Anke Reichardt

Investor at AbbVie

Azurii Collier

Commercial Advisor at 2Flo Ventures

Christian Schubert

Head of AbbVie Ventures at AbbVie

Christina Vorvis

Director at AbbVie

Claire Leurent

Managing Director at AbbVie

Doug Faunce

Executive Director at AbbVie

Joachim Vogt

Director at AbbVie

John Ballew

Senior Associate at JDRF T1D Fund

Frequently asked questions

Who is Donmienne Leung?: Donmienne Leung leads a dedicated European venture mandate and, after 20+ years as a drug hunter and PhD medicinal chemist with active publications, provides hands-on scientific guidance to biotech boards.
Where does Donmienne Leung work?: Donmienne Leung is Director II, Head of AbbVie Ventures Europe at AbbVie and Board director at EndLyz Therapeutics and CEO at ThirtyFiveBio Limited.
What does Donmienne Leung invest in?: Donmienne Leung invests in AI & Machine Learning, Biotech, Data & Infrastructure, Healthtech.
Where did Donmienne Leung go to school?: Donmienne Leung studied at The University of Queensland (Doctor, Philosophy); University of Melbourne (Bachelor of Science (Honours), Chemistry / Biochemistry); University of Melbourne (Bachelor of Science & Bachelor of Engineering, Biochemistry).

Founder mafias

University of Melbourne mafia134

Also came through, then founded or led a company.

Cameron AdamsLLB/BScFounded Canva Anthony GoldbloomCommerce (hons Economics)Founded Sumble +1 Nikhil PooviahBachelor of MedicineFounded Osara Health +1 Haakon BrunellBachelor of Science - BSFounded Katapult Accelerator +1 Jonathan BernardiniDoctor of Philosophy - PhDFounded Proxima +1 Brandon AfariCommerce (Business)Founded chargeFUZE +1

+ 127 more →

Eli Lilly mafia19

Also came through, then founded or led a company.

Dirk ReynSales ManagerFounded Spectricity +1 Jacopo LeonardiNew Product Planning ManagerFounded 4D Path +1 Michael KalosChief Scientific Officer, Cancer Immunobiology, Distinguished Lilly ScholarFounded IpiNovyx Bio Paris PanayiotopoulosGM Leadership ProgramFounded AvenCell Robert BalfourSourcing AssociateFounded Pro Matix Joe Cook JrGroup Vice President-RetiredFounded Ironwood Pharmaceuticals

+ 12 more →

AbbVie mafia17

Also came through, then founded or led a company.

Evan MurphySenior Software EngineerFounded Zitara +1 Matthew RastovacSoftware Engineering InternFounded Atmos +1 Howard BermanMedical AffairsFounded Coya Therapeutics +1 Nick GasbarroGovernment Affairs InternFounded Cognizant Ross LeimbergDirectorFounded Cantai Therapeutics Jim Sullivan, Ph.D.Vice President Global DiscoveryFounded Vanqua Bio

+ 10 more →

Enthera mafia2

Also came through, then founded or led a company.

Jonathan BehrBoard ObserverFounded Tilos Therapeutics +1

Same school

Also attended The University of Queensland217

Giuseppe IademarcoHead of Global Partnership at P101 Ventures Jasmine BettesInvestor at Reinventure Group Esther GilmoreGlobal Head of the Client Team at Generation Investment Management Nilay ThakarPrincipal at ARCH Venture Partners Zenetta BurgerPartner at Giant Ventures Global Llp Thuy-Linh UongStrategy & Corp. Development Manager at Emerald Technology Ventures Ag

+ 211 more

Also attended University of Melbourne391

Cameron AdamsCo-founder & Chief Product Officer of Canva Kevin JohnsonInvestor at Medicxi Esther GilmoreGlobal Head of the Client Team at Generation Investment Management Mark MillsClient Team Member at Generation Investment Management Clarissa KartikaAssociate, Investment at Vertex Ventures Sea Management Pte. Ltd.Rikke Kjær DamgaardAssociate at SEED Capital Denmark

+ 385 more

Shared employers

Also worked at AbbVie66

Nick GasbarroChief of Staff at QED Investors Charles White, Ph.D.Principal at Illumina Ventures Laura QuockCBO-in-Residence at Versant Ventures Manik PasrichaVice President at Titan Capital Jennifer SmoterChief Communications & Governance Officer at Takeda Ventures Takehiko SawabeDirector at Beyond Next Ventures

+ 60 more

+ 181 more

Find your path to Donmienne

About

Invests in

Board director at EndLyz Therapeutics

Intro paths

EndLyz Therapeutics's investors · 2

CEO at ThirtyFiveBio Limited

Intro paths

ThirtyFiveBio Limited's investors · 1

Experience

Skills & more

Colleagues at AbbVie

Frequently asked questions

Founder mafias

University of Melbourne mafia134

Eli Lilly mafia19

AbbVie mafia17

Enthera mafia2

Same school

Also attended The University of Queensland217

Also attended University of Melbourne391

Shared employers

Also worked at AbbVie66

Also worked at Enthera Pharmaceuticals4

Also worked at DISCO Pharmaceuticals GmbH4

Also worked at Eli Lilly and Company187